Prevest Denpro Ltd (543363)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Prevest Denpro's revenue was ₹19.1 Cr (+20.9% year on year, +0.7% on the previous quarter), and net profit ₹5.6 Cr (+27.9% year on year); the operating margin was 35.5%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹19.1 | +20.9% | +0.7% |
| Operating profit | ₹6.8 | +27.4% | -2.1% |
| Net profit | ₹5.6 | +27.9% | -3.1% |
| EPS (₹) | 4.70 | +28.1% | -3.1% |
| Operating margin | 35.5% | — | — |
📢 Recent Corporate Announcements
Prevest Denpro Limited has issued notices and Integrated Annual Report access links to shareholders whose email addresses are not registered with the RTA/Depository. The company's 27th Annual General Meeting (AGM) will be conducted virtually on September 17, 2026, at 12:30 PM IST. The cut-off date to determine shareholder voting eligibility is September 10, 2026. Remote e-voting opens on September 14, 2026, and concludes on September 16, 2026.
- 27th Annual General Meeting scheduled for September 17, 2026 at 12:30 P.M. IST via Video Conferencing.
- Cut-off date for voting eligibility set as Thursday, September 10, 2026.
- Remote e-voting window active from September 14, 2026 (09:00 AM) to September 16, 2026 (05:00 PM).
- Notice dispatched pursuant to Regulation 36(1)(b) of SEBI LODR Regulations.
Prevest Denpro has submitted its Integrated Annual Report for FY 2025-26 and convened its 27th Annual General Meeting on September 17, 2026. For FY26, the company posted consolidated revenue from operations of ₹71.81 crore (up 13.93% YoY) and consolidated PAT of ₹20.49 crore (up 12.86% YoY). Operational growth was driven by a 17.58% rise in exports and a 9% increase in domestic business across its dental biomaterials portfolio. The company maintained a debt-free balance sheet while establishing a wholly owned subsidiary in the UAE.
- Consolidated revenue from operations reached ₹71.81 crore, rising 13.93% YoY in FY26
- Consolidated PAT increased 12.86% YoY to ₹20.49 crore for FY26
- Export business grew 17.58% YoY, while domestic business expanded 9% YoY
- Maintained a debt-free balance sheet and established a new subsidiary in the UAE
- 27th Annual General Meeting scheduled for September 17, 2026 via VC/OAVM
Prevest Denpro has issued the notice for its 27th Annual General Meeting scheduled for September 17, 2026, via VC/OAVM. Key ordinary business items include the declaration of a final dividend of ₹1 per equity share (face value ₹10) for FY 2025-26 and the appointment of M/s. A D V & Associates as Statutory Auditors for a 5-year term. Special business includes the re-appointment of Mrs. Namrata Modi as Whole-Time Director and Mr. Sai Kalyan Surapaneni as Executive Director (with annual remuneration up to ₹70 lakh) for 3 years, alongside appointment of three Independent Directors.
- 27th AGM scheduled to be held on Thursday, September 17, 2026, at 12:30 p.m. IST via VC/OAVM
- Recommendation of a final dividend of ₹1 per equity share of face value ₹10 each for FY26
- Appointment of M/s. A D V & Associates as Statutory Auditors for a 5-year term until the 32nd AGM (FY 2031-32)
- Re-appointment of Executive Director Mr. Sai Kalyan Surapaneni for 3 years with annual remuneration up to ₹70,00,000
- Ratification of Cost Auditor remuneration at ₹1,00,000 per year for FY26 and FY27
Prevest Denpro reported a 20.94% YoY increase in consolidated revenue to ₹19.07 Cr for Q1 FY27, while consolidated PAT grew 27.99% to ₹5.64 Cr. The company maintained strong operational efficiency with EBITDA growing 24.73% YoY to ₹8.08 Cr, outpacing revenue growth. A dividend of ₹1 per share (10%) was recommended for FY 2025-26. The results show steady growth compared to the previous quarter, with consolidated revenue up 0.67% QoQ, continuing the momentum from FY26.
- Consolidated Revenue from Operations grew 20.94% YoY to ₹1,906.83 lakh
- Consolidated PAT increased 27.99% YoY to ₹563.86 lakh
- EBITDA grew 24.73% YoY to ₹808.14 lakh, indicating margin expansion
- Recommended a dividend of 10%, equivalent to ₹1 per equity share
- Standalone revenue grew 23.66% YoY to ₹1,944.33 lakh
Prevest Denpro has fixed September 05, 2026, as the record date to determine shareholder eligibility for the final dividend of FY 2025-26. The dividend payout is subject to approval at the upcoming 27th Annual General Meeting. This follows a strong financial year where the company reported a PAT of ₹21 Cr on a revenue of ₹72 Cr, maintaining a robust operating margin of 36%. As a debt-free company with a 25% ROCE, this move continues its trend of returning capital to shareholders.
- Record date for final dividend eligibility fixed for September 05, 2026.
- Dividend pertains to the full financial year ending March 31, 2026 (FY 2025-26).
- Payment is contingent upon approval at the company's 27th Annual General Meeting.
- Company reported FY26 revenue of ₹72.0 Cr, a 14.3% increase over FY25's ₹63.0 Cr.
- Net profit for FY26 stood at ₹21.0 Cr with an EPS of ₹17.85.
Prevest Denpro reported a strong start to FY27 with consolidated revenue growing 20.9% YoY to Rs 19.07 Cr. Consolidated net profit increased 27.9% YoY to Rs 5.64 Cr, maintaining a healthy net margin of 29.5%. The Board recommended a final dividend of Rs 1.00 per share for FY26. Results were slightly impacted by a Rs 27.80 lakh increase in employee costs following the implementation of new Labour Codes.
- Consolidated revenue from operations rose to Rs 19.07 Cr, up 20.9% from Rs 15.77 Cr in Q1 FY26.
- Consolidated Net Profit reached Rs 5.64 Cr compared to Rs 4.41 Cr in the same quarter last year.
- Recommended a final dividend of 10% (Rs 1.00 per equity share) for FY 2025-26.
- Employee benefit expenses increased by Rs 27.80 lakh due to the implementation of new Labour Codes effective April 1, 2026.
- Foreign subsidiaries (Axiodent Inc. and Prevest Denpro Gulf) reported a combined net loss of Rs 16.81 Lakhs.
Prevest Denpro reported a strong start to FY27 with consolidated revenue rising 20.9% YoY to Rs 19.07 Cr. Consolidated Net Profit grew 27.9% YoY to Rs 5.64 Cr, significantly outpacing the company's long-term 15% CAGR target. The board recommended a final dividend of Rs 1.00 per share (10% of face value) for FY26. Profitability remained robust with a PBT margin of 39.6%, even after absorbing a Rs 27.80 lakh increase in employee costs due to new Labour Code implementations.
- Consolidated Revenue from operations increased 20.9% YoY to Rs 19.07 Cr from Rs 15.77 Cr.
- Consolidated Net Profit rose 27.9% YoY to Rs 5.64 Cr compared to Rs 4.41 Cr in Q1 FY26.
- Recommended a final dividend of Rs 1.00 per equity share (10% of face value) for FY26.
- Employee benefit expenses increased by Rs 27.80 lakh due to the implementation of new Labour Codes effective April 1, 2026.
- Foreign subsidiaries Axiodent Inc. and Prevest Denpro Gulf reported a combined net loss of Rs 16.81 Lakhs on revenue of Rs 5.71 Lakhs.
Prevest Denpro has scheduled a board meeting on August 11, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). Additionally, the board will consider recommending a final dividend for the full financial year 2025-26. The company recently concluded FY26 with a revenue of ₹72 Cr and a PAT of ₹21 Cr, maintaining a strong operating margin of 36%. Investors will be watching for the dividend payout ratio relative to the FY26 EPS of ₹17.85.
- Board meeting scheduled for August 11, 2026, to review Q1 FY27 performance.
- Final dividend recommendation for FY25-26 is on the agenda.
- Company reported TTM revenue of ₹72 Cr and PAT of ₹21 Cr as of March 2026.
- Operating profit margin remains robust at 35.6% based on TTM figures.
- Promoter holding remains stable at 73.6% as of June 2026.
Financial Performance
Revenue Growth by Segment
Total revenue for FY 2024-25 was INR 63 Cr, up 12.5% YoY. For H1 FY26, revenue from operations reached INR 34.41 Cr, a 16.14% YoY increase. Export revenue grew by 24% YoY in H1 FY26, while domestic growth slowed to 5% due to Q1 events like elections and heatwaves.
Geographic Revenue Split
Exports continue to form a significant part of revenue, growing 24% YoY in H1 FY26. Domestic markets contributed the remainder, though growth was lower at 5% in the same period.
Profitability Margins
H1 FY26 PAT margin stood at 27.06% (INR 9.95 Cr), up 17.20% YoY. FY 2024-25 ROCE was 23% and ROE was 17%, both down 1% YoY due to increased inventory levels.
EBITDA Margin
H1 FY26 EBITDA margin was 39.04% (INR 14.35 Cr), reflecting a 17.36% YoY growth in EBITDA. Management maintains a disciplined focus on high-margin value-added products to sustain these levels.
Capital Expenditure
Total Capex for FY 2024-25 was INR 2 Cr, focused on the upgradation of equipment and R&D infrastructure.
Credit Rating & Borrowing
The company remains debt-free as of H1 FY26, providing financial flexibility for future growth plans without interest strain.
Operational Drivers
Raw Materials
Dental materials including adhesives, composites, endodontics, acrylics, waxes, and impression materials (specific chemical names like Bis-GMA or TEGDMA not explicitly listed).
Capacity Expansion
Current capacity in units not disclosed; however, the company is focused on automation and equipment upgradation with a recent INR 2 Cr Capex to support future demand.
Raw Material Costs
Input costs are managed through planning cycles and supplier diversification to mitigate supply chain delays; specific cost as % of revenue not disclosed.
Manufacturing Efficiency
Focus on automation and digital integration to maintain margins; H1 FY26 EBITDA margin of 39.04% reflects high operational efficiency.
Strategic Growth
Expected Growth Rate
15%
Growth Strategy
Growth will be achieved through a 15% CAGR target to cross INR 100 Cr revenue within 3 years. Key strategies include expanding digital dentistry and 3D printing resins, scaling the 'Prevest Direct' e-commerce platform, and penetrating international markets via subsidiaries like Axiodent Inc and joint ventures.
Products & Services
Dental materials including adhesives, composites, endodontics, acrylics, waxes, impression materials, and 3D printing resins.
Brand Portfolio
Prevest DenPro, Prevest Direct, DenVisio.
New Products/Services
Expansion into digital dentistry and 3D-based products, which are expected to become a larger share of the portfolio in coming years.
Market Expansion
Targeting deeper engagement in international markets through localized operations and strategic partnerships, particularly in emerging and developed regions.
Strategic Alliances
Research collaborations with prominent academic institutes and the incorporation of WOS Axiodent Inc and subsidiary DenVisio Biomed Limited.
External Factors
Industry Trends
The industry is shifting toward digital dentistry and 3D printing; Prevest is positioning itself by investing in 3D-based products to capture this evolving market segment.
Competitive Landscape
Facing increasing competition and price sensitivity across global geographies, countered by a focus on high-value products.
Competitive Moat
Moat is built on 40+ years of promoter experience, a portfolio of 100+ products, and research-led development of high-margin value-added products, ensuring sustainable 39% EBITDA margins.
Macro Economic Sensitivity
Sensitive to global trade conditions and domestic political events (e.g., elections) which impacted H1 FY26 domestic growth.
Consumer Behavior
Rising demand for core dental materials and increasing traction in digital and 3D-printing product categories.
Geopolitical Risks
Global trade conditions and changes in export regulations are monitored as key market risks.
Regulatory & Governance
Industry Regulations
Compliance with global medical standards and export regulations is managed by dedicated monitoring teams.
Environmental Compliance
Focusing on ESG compliance as part of the strategic outlook for FY 2025-26; specific costs not disclosed.
Taxation Policy Impact
Effective tax rate for H1 FY26 was approximately 25.5% (PBT of INR 13.36 Cr vs PAT of INR 9.95 Cr).
Legal Contingencies
No pending court cases or case values disclosed in available documents.
Risk Analysis
Key Uncertainties
Forex fluctuations and changes in global demand are primary uncertainties with potential impact on the 24% export growth rate.
Geographic Concentration Risk
Significant revenue concentration in export markets; H1 FY26 export growth was 24% compared to 5% domestic growth.
Third Party Dependencies
Mitigated through supplier diversification to prevent supply chain disruptions.
Technology Obsolescence Risk
Mitigated by continuous R&D in 3D printing and digital dentistry to stay ahead of technology shifts.
Credit & Counterparty Risk
Credit risk from customers is managed through strong receivables follow-up and conservative accounting.
